

CITATION REPORT

List of articles citing

Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review

DOI: 10.1093/humupd/8.6.559

Human Reproduction Update, 2002, 8, 559-77.

Source: <https://exaly.com/paper-pdf/33633101/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
553	Prevention of Ovarian Hyperstimulation Syndrome. 2001 , 130-199		1
552	Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. 2003 , 7, 313-8		22
551	Stem cell research: why medicine should reject human cloning. 2003 , 78, 1010-8		1
550	Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. 2003 , 349, 760-6		223
549	Stem Cell Research: Why Medicine Should Reject Human Cloning. 2003 , 78, 1010-1018		3
548	Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients. 2004 , 89, 3561-6		42
547	Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits. 2004 , 72, 184-9		1
546	Increased erythrocyte aggregation in ovarian hyperstimulation syndrome: a possible contributing factor in the pathophysiology of this disease. <i>Human Reproduction</i> , 2004 , 19, 1076-80	5.7	9
545	Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. 2004 , 89, 6310-5		116
544	New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. <i>Human Reproduction</i> , 2004 , 19, 486-9	5.7	62
543	Coasting acts through downregulation of VEGF gene expression and protein secretion. <i>Human Reproduction</i> , 2004 , 19, 1530-8	5.7	44
542	Ovarian hyperstimulation syndrome. 2004 , 20, 679-95, ix		23
541	Adnexal mass with pelvic pain. 2004 , 42, 329-48		48
540	Oocyte quality in patients with severe ovarian hyperstimulation syndrome: a self-controlled clinical study. 2004 , 82, 827-33		14
539	Ovarian hyperstimulation syndrome. 2005 , 33, S301-6		88
538	Understanding ovarian hyperstimulation syndrome. 2005 , 26, 285-90		38
537	Egg-sharing: a critical view. 2005 , 7, 109-111		4

536 Mode of delivery of twins. **2005**, 7, 137-137

535 Author's reply. **2005**, 7, 137-138

534 Severe ovarian hyperstimulation syndrome in a 42-year-old woman with successful pregnancy after intracytoplasmic sperm injection embryo transfer. **2005**, 4, 265-269 1

533 Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review*. **2005**, 84, 611-6 27

532 Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. **2005**, 84, 611-616 65

531 Estrogen-induced abnormally high cystic fibrosis transmembrane conductance regulator expression results in ovarian hyperstimulation syndrome. **2005**, 19, 3038-44 25

530 Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. *Human Reproduction*, **2005**, 20, 2421-5 5-7 50

529 Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. *Human Reproduction*, **2005**, 20, 3167-72 5-7 65

528 What have gonadotrophin overexpressing transgenic mice taught us about gonadal function?. **2005**, 130, 283-91 29

527 Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. **2005**, 83, 1695-9 32

526 Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?. **2005**, 83, 1607-11 61

525 Can we eliminate severe ovarian hyperstimulation syndrome?. *Human Reproduction*, **2005**, 20, 320-2 5-7 82

524 Ovum pick up and in vitro embryo production in cows superstimulated with an individually adapted superstimulation protocol. **2005**, 86, 13-25 20

523 Pharmacogenetics of controlled ovarian hyperstimulation. **2005**, 6, 629-37 22

522 Economic evaluation of the administration of follitropin-beta with a pen device. **2005**, 11, 26-35 7

521 The science behind 25 years of ovarian stimulation for in vitro fertilization. **2006**, 27, 170-207 389

520 Egg harvesting for stem cell research: medical risks and ethical problems. **2006**, 13, 573-9 49

519 Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing?. **2006**, 85, 547-54 56

518	Effect of coasting on cycle outcome during in vitro fertilization/intracytoplasmic sperm injection cycles in hyper-responders. 2006 , 85, 913-7		22
517	Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome. 2006 , 86, 1710-5		16
516	Outcomes from assisted reproductive technology. 2006 , 107, 183-200		59
515	Fair payment or undue inducement?. 2006 , 442, 629-30		48
514	No association between the microsatellite polymorphism (TTTTA) _n in the promoter of the CYP11A gene and ovarian hyperstimulation syndrome. 2006 , 23, 29-32		3
513	An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. 2006 , 120, 293-9		20
512	Fertility in patients with multiple sclerosis: current knowledge and future perspectives. 2006 , 27, 231-9		92
511	Ovarian hyperstimulation syndrome: Aetiology, prevention and management. 2006 , 6, 26-32		3
510	The CryoLoop facilitates re-vitrification of embryos at four successive stages of development without impairing embryo growth. <i>Human Reproduction</i> , 2006 , 21, 2978-84	5:7	37
509	Gonadotropin-releasing hormone antagonist in in vitro fertilization superovulation. 2006 , 2, 881-8		2
508	A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. <i>Human Reproduction Update</i> , 2006 , 12, 13-21	15.8	270
507	Genetic predictors of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. 2006 , 2, 590-1		8
506	Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2006 , 12, 651-71	15.8	238
505	GnRH antagonists in ovarian stimulation for IVF. <i>Human Reproduction Update</i> , 2006 , 12, 333-40	15.8	179
504	Absence of mutation in the follicle-stimulating hormone receptor gene in severe primary hypothyroidism associated with gonadal hyperstimulation. 2007 , 20, 923-31		7
503	Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. <i>Human Reproduction</i> , 2007 , 22, 3210-4	5:7	91
502	Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. 2007 , 10, 75-85		61
501	In vitro fertilization in the polycystic ovary syndrome patient: an update. 2007 , 50, 268-76		8

500	The effect of withholding gonadotropin (a coasting period) on the outcome of in vitro fertilization cycles. 2007 , 133, 81-5	9
499	[In vitro fertilization (IVF): why doing it in unstimulated cycles?]. 2007 , 35, 877-80	3
498	Polycystic ovary syndrome. 2007 , 370, 685-97	998
497	Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research. 2007 , 10, 183-7	41
496	Odds of ovarian hyperstimulation syndrome (OHSS) - time for reassessment. 2007 , 10, 175-81	38
495	Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. <i>Human Reproduction</i> , 2007 , 22, 2414-21 5-7	318
494	Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. 2007 , 92, 2931-7	162
493	A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. 2007 , 15, 271-9	49
492	Towards a more physiological approach to IVF. 2007 , 14, 550-2	47
491	Donating fresh versus frozen embryos to stem cell research: in whose interests?. 2007 , 21, 465-77	27
490	Cytological features of benign mesothelial inclusions in lymph node: a case report of a patient presenting with cervical lymphadenopathy after in vitro fertilization. 2007 , 18, 56-8	3
489	Risiken der ovariellen Stimulation zur IVF. 2007 , 40, 773-779	1
488	Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles. 2007 , 24, 331-6	12
487	Catastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation. 2007 , 26, 991-3	16
486	Neue Ansätze bei der Prävention des ovariellen Überstimulationssyndroms. 2008 , 6, 165-170	3
485	Comparison of symptomatology in Taiwanese women pregnant with and without assisted reproductive technology. 2008 , 31, 208-16	1
484	Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. 2008 , 17, 237-43	124
483	Optimal follicle and oocyte numbers for cryopreservation of all embryos in IVF cycles at risk of OHSS. 2008 , 17, 312-7	17

482	Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. <i>Human Reproduction Update</i> , 2008 , 14, 1-14	15.8	155
481	Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)?. 2008 , 70, 1174-8		14
480	The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. 2008 , 89, 84-91		341
479	The incidence of both serious and minor complications in young women undergoing oocyte donation. 2008 , 90, 2165-71		95
478	Mild ovarian stimulation for IVF. <i>Human Reproduction Update</i> , 2009 , 15, 13-29	15.8	132
477	Oocyte markets: women's reproductive work in embryonic stem cell research. 2008 , 27, 19-31		73
476	Ovulation triggers in anovulatory women undergoing ovulation induction. 2008 , CD006900		0
475	Human oocyte research: the ethics of donation and donor protection. 2008 , 300, 2174-6		11
474	THE BIOPOLITICS OF REPRODUCTION. 2008 , 23, 57-73		105
473	Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. 2008 , 65, 1148-53		21
472	3D ultrasound in gynecology and reproductive medicine. 2008 , 4, 501-16		12
471	Cervical insemination versus intra-uterine insemination of donor sperm for subfertility. 2008 , CD000317		17
470	Ovulation triggers in anovulatory women undergoing ovulation induction. 2008 ,		1
469	Ova donation for stem cell research: An international perspective. 2008 , 1, 125-144		19
468	Thrombosis of subclavian and internal jugular veins following severe ovarian hyperstimulation syndrome: a case report. 2008 , 30, 590-597		8
467	Is there a place for natural or modified natural cycles?. 2008 , 3, 449-453		
466	Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. 2008 , 121, 2434-2439		8
465	[Treatment of infertility in women with polycystic ovary syndrome]. 2008 , 30, 201-9		3

- 464 In vitro maturation (IVM) as a new technique to treat polycystic ovary syndrome (PCOS) and induce pregnancy in Indonesia. **2009**, 269
- 463 Complications of ovulation induction II: ovarian hyperstimulation syndrome, ovarian torsion. 151-159
- 462 Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. **2009**, 4, 299-311 16
- 461 Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. *Human Reproduction*, **2009**, 24, 1191-9 5-7 37
- 460 Ethical issues in bone repair and bone tissue engineering. **2009**, 441-464
- 459 [Magnetic resonance for evaluating the response to treatment for ovarian hyperstimulation syndrome: comparison of pharmacokinetic models.]. **2009**, 51, 176-82 2
- 458 Ovarian hyperstimulation syndrome and complications of ART. **2009**, 23, 691-709 68
- 457 Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome?. **2009**, 33, 583-91 18
- 456 Polycystic ovarian syndrome: a misnomer for an enigmatic disease. **2009**, 33, 621-7 8
- 455 Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. **2009**, 92, 1953-9 35
- 454 [Is the stability of results in IVF possible?]. **2009**, 38, 312-20
- 453 Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. **2009**, 18, 630-4 96
- 452 Symposium: Update on prediction and management of OHSS. *Epidemiology of OHSS*. **2009**, 19, 8-13 58
- 451 Debate in embryo donation: embryo donation or both-gamete donation?. **2009**, 19 Suppl 1, 29-33 5
- 450 Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. **2009**, 18, 195-204 84
- 449 Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. **2009**, 88, 1373-81 26
- 448 Medical Approaches to Ovarian Stimulation for Infertility. **2009**, 689-724 2
- 447 Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. *Gynecological Endocrinology*, **2009**, 25, 60-6 2.4 66

446	A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. <i>Human Reproduction</i> , 2009 , 24, 3063-72	5.7	182
445	Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. 2009 , 19, 789-95		18
444	Optimal control of dosage decisions in controlled ovarian hyperstimulation. 2010 , 178, 223-245		11
443	Recombinant follicle-stimulating hormone (follitropin alfa) for ovulation induction in Japanese patients with anti-estrogen-ineffective oligo- or anovulatory infertility: results of a phase II dose-response study. 2010 , 9, 91-97		3
442	Recombinant follicle-stimulating hormone (follitropin alfa) versus purified urinary follicle-stimulating hormone in a low-dose step-up regimen to induce ovulation in Japanese women with anti-estrogen-ineffective oligo- or anovulatory infertility: results of a single-blind Phase III study. 2010 , 9, 99-106		5
441	Ovarian hyperstimulation syndrome: pathophysiology and prevention. 2010 , 27, 121-8		142
440	Síndrome de hiperestimulación ovárica. 2010 , 17, 435-436		
439	[Severe ovarian hyperstimulation syndrome: a case report]. 2010 , 34, 81-2		0
438	Oral agents for ovarian stimulation. 1-13		
437	Mild approaches in ovarian stimulation. 34-41		
436	Ovarian hyperstimulation for poor responders. 77-86		
435	Ovarian hyperstimulation syndrome. 103-129		
434	Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. 2010 , 70, 47-54		16
433	Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. 2010 , 3, 85-90		14
432	Assisted Reproduction. 2010 , 469-504		2
431	Riesgos y complicaciones de los tratamientos de infertilidad. 2010 , 21, 457-462		
430	Ultrasound and its role in assisted reproduction treatment. 2010 , 2, 135-150		1
429	GnRH α to trigger final oocyte maturation: a time to reconsider. <i>Human Reproduction</i> , 2010 , 25, 559	5.7	3

428	Critical care management of obstetric emergencies. 2010 , 71, 382-7	1
427	Ovarian hyperstimulation syndrome: definition, incidence, and classification. 2010 , 28, 441-7	38
426	Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. 2010 , 28, 463-7	10
425	Identification of the high-risk patient for ovarian hyperstimulation syndrome. 2010 , 28, 458-62	38
424	Ovarian hyperstimulation syndrome (OHSS) due to mutations in the follicle-stimulating hormone receptor. 2010 , 71, 206-9	11
423	Review: follicular waves in the human ovary: a new physiological paradigm for novel ovarian stimulation protocols. 2010 , 17, 1067-76	23
422	[Ovarian hyperstimulation syndrome in a 19-years-old woman]. 2010 , 135, 723-4	
421	Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization. 2010 , 93, 167-73	27
420	Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. 2010 , 93, 1215-9	36
419	Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. 2010 , 93, 2281-4	53
418	Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome. 2010 , 94, 173-8	30
417	The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1,068 coasted cycles to prevent ovarian hyperstimulation. 2010 , 94, 1757-63	16
416	Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. 2010 , 94, 1111-4	37
415	Proposed oocyte donation guidelines for stem cell research. 2010 , 94, 2503-6	8
414	Spontaneous ovarian hyperstimulation syndrome in a naturally conceived singleton pregnancy. 2010 , 94, 351.e1-4	7
413	Preventing ovarian hyperstimulation syndrome: guidance for the clinician. 2010 , 94, 389-400	227
412	Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility. 2010 , 20, 182-90	11
411	Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study. 2010 , 21, 159-65	7

410	[Induction of ovulation]. 2010 , 39, S67-74		0
409	Excessive ovarian stimulation up-regulates the Wnt-signaling molecule DKK1 in human endometrium and may affect implantation: an in vitro co-culture study. <i>Human Reproduction</i> , 2010 , 25, 479-90	5.7	62
408	Ultrasound Evaluation of Gynecologic Causes of Pelvic Pain. 2010 , 5, 209-231		1
407	GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. <i>Human Reproduction Update</i> , 2011 , 17, 510-24	15.8	229
406	Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. <i>Human Reproduction Update</i> , 2011 , 17, 184-96	15.8	77
405	Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. 2011 , 22 Suppl 1, S73-82		25
404	Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. 2011 , CD001302		32
403	Ultrasound evaluation of gynecologic causes of pelvic pain. 2011 , 38, 85-114, viii		46
402	[Ovarian hyperstimulation syndrome]. 2011 , 30, 353-62		5
401	Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. 2011 , 95, 188-96, 196.e1-3		29
400	Migraines and ovarian hyperstimulation syndrome: a dopamine connection. 2011 , 95, 417-9		6
399	Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. 2011 , 95, 673-8		17
398	Late ovarian hyperstimulation syndrome after controlled ovarian stimulation in a woman with systemic lupus erythematosus and lupus nephritis. 2011 , 95, 1786.e13-6		2
397	Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control study. 2011 , 95, 1629-32		32
396	Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. 2011 , 95, 2429.e5-7	6	
395	Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. 2011 , 96, 53-7		21
394	Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. 2011 , 96, 1384-1390.e4		58
393	Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study. 2011 , 159, 143-7		13

392	Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome. 2011 , 335, 116-25	20
391	[Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment]. 2011 , 40, 593-611	18
390	Molecular and cellular integrity of cultured follicles. 389-396	
389	In vitro maturation of GV oocytes. 421-430	1
388	Abdominal and pelvic pain in early pregnancy. 81-102	
387	High-response intrauterine insemination cycles converted to low-cost in vitro fertilization. 2011 , 4, 119-24	1
386	Pharmacogenetics of ovarian stimulation in the twenty-first century. 80-87	1
385	Ovarian hyperstimulation syndrome. 127-151	
384	Current status and future trends of the clinical practice of human oocyte in vitro maturation. 186-198	9
383	The diagnosis and management of ovarian hyperstimulation syndrome. 2011 , 33, 1156-1162	33
382	Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome. 2011 , 16, 56-60	9
381	Sicherere In-vitro-Fertilisation. 2011 , 44, 116-121	1
380	Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. 2011 , 28, 1197-203	56
379	Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function. 2011 , 12, 303-21	39
378	AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. <i>Human Reproduction Update</i> , 2011 , 17, 46-54	15.8 291
377	The redesigned follitropin pen injector for infertility treatment. 2011 , 8, 833-9	16
376	Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation? <i>Gynecological Endocrinology</i> , 2011 , 27, 862-6	2.4 9
375	Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH. 2011 , 152, 4350-7	33

374	Ovarian hyperstimulation syndrome. 2011 , 4, 70-5		103
373	Severe ovarian hyperstimulation syndrome: Intensive care management of two cases. 2011 , 1, 92		
372	Factor V Leiden and prothrombin gene G20210A mutation and in vitro fertilization: prospective cohort study. <i>Human Reproduction</i> , 2011 , 26, 3068-77	5.7	33
371	Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. <i>Gynecological Endocrinology</i> , 2011 , 27, 117-20	2.4	12
370	Longer Duration and Lower Fatal Risk of Late-onset Pregnancy-related Ovarian Hyperstimulation Syndrome. 2011 , 7, 357-363		
369	Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. 2012 , 5, 32-6		6
368	Spontaneous ovarian hyperstimulation syndrome in a triplet pregnancy. 2012 , 2012, 189705		4
367	A comparative study between cabergoline, coasting, and step-down regimens in the prevention of severe OHSS and their correlation with pregnancy rate in intracytoplasmic sperm injection cycles. 2012 , 2, 121-125		1
366	New York State's landmark policies on oversight and compensation for egg donation to stem cell research. 2012 , 7, 397-408		9
365	Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. <i>Human Reproduction</i> , 2012 , 27, 196-9	5.7	30
364	Doppler imaging in the diagnosis of ovarian disease. 2012 , 6, 59-73		1
363	Future developments to minimize ART risks. 2012 , 30, 152-60		5
362	The role of ultrasound in early pregnancy after assisted conception. 14-35		
361	Serum albumin levels in women with ovarian hyperstimulation syndrome with or without polycystic ovaries. 2012 , 34, 866-869		
360	Ovarian stimulation protocols in assisted reproductive technology: an update. 2012 , 7, 319-330		4
359	Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. 2012 , 24, 410-9		22
358	GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes. 2012 , 25, 284-91		19
357	Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome. 2012 , 32, 379-82		6

356	Oocytes for research: inspecting the commercialization continuum. 2012 , 31, 135-157		11
355	The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. 2012 , 116, 268-73		9
354	Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. 2012 , 98, 888-92		71
353	Approximate dynamic programming algorithms for optimal dosage decisions in controlled ovarian hyperstimulation. 2012 , 222, 328-340		13
352	Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyper stimulation syndrome. 2012 , 13, 23		5
351	The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. 2012 , 12, 29		43
350	Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reproductive Biology and Endocrinology</i> , 2012 , 10, 32	5	81
349	Study of Combined Use of Clomiphene Citrate and Gonadotropins on the Infertile Patients with PCOS. 2012 , 23, 159-168		
348	Emergency ultrasound diagnosis of ovarian hyperstimulation syndrome: case report. 2012 , 43, e129-32		6
347	Egg donation for stem cell research: ideas of surplus and deficit in Australian IVF patients' and reproductive donors' accounts. 2012 , 34, 513-28		14
346	Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report. 2012 , 29, 127-9		3
345	Do estrogen receptor alpha polymorphisms have any impact on the outcome in an ART program?. 2013 , 30, 555-61		2
344	Targeting angiogenesis in the pathological ovary. 2013 , 25, 362-71		14
343	The role of osmoregulation in the pathophysiology and management of severe ovarian hyperstimulation syndrome. 2013 , 16, 162-7		5
342	Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. 2013 , 100, 420-9.e7		117
341	Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. 2013 , 170, 439-43		8
340	Spontaneous ovarian hyperstimulation syndrome: case report, pathophysiological classification and diagnostic algorithm. 2013 , 169, 143-8		11
339	Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization. 2013 , 99, 970-8.e1		44

338	Ovarian stimulation in cancer patients. 2013 , 99, 1476-84		91
337	The effect of cabergoline on follicular microenvironment profile in patients with high risk of OHSS. <i>Gynecological Endocrinology</i> , 2013 , 29, 749-53	2.4	9
336	Involvement of the ANGPTs/Tie-2 system in ovarian hyperstimulation syndrome (OHSS). 2013 , 365, 223-30		15
335	Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. <i>Gynecological Endocrinology</i> , 2013 , 29, 98-100	2.4	11
334	Assistierte Reproduktion. 2013 , 46, 37-41		
333	Ovarian Hyperstimulation Syndrome: incidence in a public service of assisted reproduction and literature review. 2013 , 28, 10-17		1
332	Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. 2013 , 26, 562-8		22
331	Low tolerance for complications. 2013 , 100, 299-301		6
330	Compliance with donor age recommendations in oocyte donor recruitment advertisements in the USA. 2013 , 26, 400-5		11
329	Rodent models of polycystic ovary syndrome. 2013 , 373, 2-7		30
328	LH supplementation in mild stimulations cycles without pituitary suppression: a retrospective analysis. <i>Gynecological Endocrinology</i> , 2013 , 29, 101-4	2.4	
327	Abdominal Compartment Syndrome Due to OHSS. 2013 , 63, 350-3		6
326	Ovarian hyperstimulation syndrome as an etiology of obstructive uropathy. 2013 , 2013, 653704		7
325	Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome. 2013 , 6, 248-52		17
324	Ovarian Hyperstimulation Syndrome (OHSS) Presented as Massive Hydrothorax. 2013 , 7, 2996-7		5
323	Biology and Regulation of Blood-Tissue Barriers. 2013 ,		2
322	Mild ovarian stimulation for in vitro fertilization: are we ready to change? A meta-analysis. 2013 , 76, 233-40		13
321	The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. 2013 , 98, E472-84		43

320	Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. 2013 , 16, 151-9		17
319	Give Me Children or Else I Die: The Politics and Policy of Cross-Border Reproductive Care. 2013 , 41, 5-38		4
318	Improving oocyte maturation in vitro. 212-223		3
317	Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle. 2014 , 41, 140-5		5
316	Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients. 2014 , 2, 246		11
315	A Comparative Study between GnRH Antagonist and Long Agonist Protocols in Patients with Polycystic Ovarian Syndrome (PCOS) Undergoing in vitro Fertilization. 2014 , 03,		
314	British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. 2014 , 17, 257-68		19
313	Dopamine agonists in prevention of ovarian hyperstimulation syndrome. <i>Gynecological Endocrinology</i> , 2014 , 30, 845-9	2.4	11
312	Neutrophil to lymphocyte ratio is superior to platelet to lymphocyte ratio as an early predictor of moderate/severe ovarian hyperstimulation syndrome. 2014 , 34, 639-43		14
311	Laparoscopic detorsion for bilateral ovarian torsion in a singleton pregnancy with spontaneous ovarian hyperstimulation syndrome. 2014 , 7, 66-8		14
310	Aromatase Inhibitor for Prevention of Ovarian Hyperstimulation Syndrome(OHSS). 2014 , 02,		
309	Ovulation triggers in anovulatory women undergoing ovulation induction. 2014 , CD006900		8
308	The prevention of ovarian hyperstimulation syndrome. 2014 , 36, 1024-1033		48
307	Cardiovascular dysfunction in offspring of ovarian-hyperstimulated women and effects of estradiol and progesterone: a retrospective cohort study and proteomics analysis. 2014 , 99, E2494-503		37
306	IVF and breast cancer: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2014 , 20, 106-23	15.8	59
305	Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. 2014 , 17, 96-104		40
304	Ovarian Hyperstimulation Syndrome (OHSS). 2014 , 213-226		1
303	Recombinant human thyrotropin use resulting in ovarian hyperstimulation: an unusual side effect. 2014 , 3, 125-9		3

302	Lesbian shared biological motherhood: the ethics of IVF with reception of oocytes from partner. 2014 , 17, 347-55		20
301	VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. 2014 , 70, 58-63		26
300	Endocrine Emergencies. 2014 ,		
299	Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer. <i>Gynecological Endocrinology</i> , 2014 , 30, 868-71	2.4	54
298	Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. 2014 , 102, 1468-1476.e1		18
297	GnRHa trigger for final oocyte maturation: is HCG trigger history?. 2014 , 29, 274-80		33
296	Differential expression of inflammation-related genes in the ovarian stroma and granulosa cells of PCOS women. 2014 , 20, 49-58		68
295	Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome. 2014 , 144 Pt B, 392-401		10
294	Medical Approaches to Ovarian Stimulation for Infertility. 2014 , 701-733.e8		1
293	Thrombosis following ovarian hyperstimulation syndrome. <i>Gynecological Endocrinology</i> , 2014 , 30, 764-8	2.4	24
292	Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome. <i>Reproductive Biology and Endocrinology</i> , 2014 , 12, 36	5	4
291	Coasting, embryo development and outcomes of blastocyst transfer: a case-control study. 2014 , 29, 231-8		5
290	[Cerebral infarction after ovarian hyperstimulation in the era of thrombolysis]. 2014 , 170, 197-204		1
289	Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). 2014 , CD005289		31
288	Severe ovarian hyperstimulation syndrome complicated by <i>Stenotrophomonas maltophilia</i> peritonitis: a case report and literature review. 2015 , 54, 1149-52		1
287	Ovarian hyperstimulation syndrome, the master of disguise?. 2015 , 2015, 510815		2
286	Prevention of Ovarian Hyperstimulation Syndrome: A Review. 2015 , 2015, 514159		44
285	Luteal phase support in in vitro fertilization. 2015 , 33, 118-27		35

284	Ovarian hyperstimulation syndrome. 2015 , 8, 531-538		1
283	Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection. 2015 , 8, 25-9		9
282	An IVF pregnancy, a neck lump and shortness of breath. 2015 , 15, 562-4		
281	A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation. 2015 , 54, 583-7		3
280	Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles. 2015 , 314, 2654-2662		107
279	Critical illness in pregnancy: part I: an approach to a pregnant patient in the ICU and common obstetric disorders. 2015 , 148, 1093-1104		31
278	Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. 2015 , 35, 1086-94		20
277	GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. 2015 , 6, 341-9		20
276	Can repeated IVF-ICSI-cycles be avoided by using blastocysts developing from poor-quality cleavage stage embryos?. 2015 , 30, 241-7		20
275	Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. 2015 , 8, 13-7		14
274	In vitro maturation is associated with increased early embryo arrest without impairing morphokinetic development of useable embryos progressing to blastocysts. <i>Human Reproduction</i> , 2015 , 30, 1842-9	5.7	39
273	Gonadotropins for Women with Unexplained Infertility. 2015 , 283-289		
272	Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model. <i>Archives of Gynecology and Obstetrics</i> , 2015 , 292, 1145-52 ^{2.5}		15
271	Disorders of Thrombosis and Hemostasis in Pregnancy. 2015 ,		
270	Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. 2015 , 30, 248-57		35
269	Being mindful of later-life sleep quality and its potential role in prevention. 2015 , 175, 502-3		2
268	Reducing Risk in Fertility Treatment. 2015 ,		
267	Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. 2015 , 103, 870-3		42

266	Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy. 2015 , 18, 248-52	5
265	'Luteal coasting' after GnRH agonist trigger - individualized, HCG-based, progesterone-free luteal support in 'high responders': a case series. 2015 , 31, 747-51	29
264	Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. 2015 , 100, 3322-31	87
263	Thrombotic and Hemostatic Aspects of Assisted Conception. 2015 , 411-423	
262	The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups. 2015 , 61, 336-44	4
261	[In vitro fertilization and systemic lupus erythematosus or antiphospholipid syndrome: An update]. 2015 , 36, 154-8	9
260	The Commodification of Women's Reproductive Tissue and Services. 2016 ,	0
259	Herbal Medicines and Ovarian Hyperstimulation Syndrome: A Retrospective Cohort Study. 2016 , 2016, 7635185	
258	Ovarian Hyperstimulation and Oocyte Harvesting Prior to Systemic Chemotherapy-A Possible Pitfall in 18F-FDG PET/CT Staging of Oncologic Patients. 2016 , 41, e394-6	3
257	C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome. 2016 , 207, 162-168	7
256	Prévention du syndrome d'hyperstimulation ovarienne. 2016 , 38, S512-S524	
255	Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art. 2016 , 12, 1731-41	6
254	Volume expanders for the prevention of ovarian hyperstimulation syndrome. 2016 , CD001302	10
253	Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. 2016 ,	0
252	Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome. 2016 , 22, 852-866	11
251	Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. 2016 , 375, 523-33	377
250	Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. <i>Human Reproduction Update</i> , 2016 , 22, 709-724	15.8 196
249	[Is gonadotropin releasing hormone (GnRH) agonist trigger beneficial or deleterious?]. 2016 , 44, 403-9	

248	hCG-induced Sprouty2 mediates amphiregulin-stimulated COX-2/PGE2 up-regulation in human granulosa cells: a potential mechanism for the OHSS. 2016 , 6, 31675		9
247	Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis. 2016 , 6, 19093		20
246	An update on the prevention of ovarian hyperstimulation syndrome. 2016 , 12, 496-503		9
245	Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. 2016 , 4, CD001750		112
244	Endokrinologische Notfälle in der Gynäkologie. 2016 , 49, 40-45		
243	Kisspeptin across the human lifespan:evidence from animal studies and beyond. 2016 , 229, R83-98		31
242	Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. <i>Human Reproduction</i> , 2016 , 31, 1997-2004	5-7	75
241	Opiate receptor blockade on human granulosa cells inhibits VEGF release. 2016 , 32, 316-22		8
240	GnRH agonist trigger does not always cause luteolysis: a case report. 2016 , 32, 132-4		7
239	Minimal stimulation IVF vs conventional IVF: a randomized controlled trial. 2016 , 214, 96.e1-8		28
238	Ovarian Stimulation Protocols. 2016 ,		6
237	Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn-Suspension After Single Subcutaneous Injection in Female Rats. 2017 , 42, 251-259		5
236	Use of Point-of-Care Ultrasound for the Diagnosis of Ovarian Hyperstimulation Syndrome. 2017 , 52, e101-e1048		
235	Fertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures. 2017 , 44, 613-618		27
234	Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. 2017 , 1, CD012103		50
233	The Ovarian Follicle of Cows as a Model for Human. 2017 , 127-144		8
232	Treatment of Ovarian Hyperstimulation Syndrome. 141-148		
231	Appendix A: Cryotech Vitrification Thawing. 2017 , 1568, 281-295		10

230	Cryopreservation of Mammalian Gametes and Embryos. 2017,	3
229	Development of In Vitro Maturation for Human Oocytes. 2017,	2
228	Reduced Intellectual Ability in Offspring of Ovarian Hyperstimulation Syndrome: A Cohort Study. 2017, 20, 263-267	12
227	Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?. 2017, 72, 296-308	10
226	Tubal anastomosis after previous sterilization: a systematic review. <i>Human Reproduction Update</i> , 2017, 23, 358-370	15.8 28
225	In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome. 2017, 23, 417-427	7
224	Does GnRH Agonist Triggering Control Painful Symptom Scores During Assisted Reproductive Technology? A Retrospective Study. 2017, 24, 1325-1333	5
223	Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles. 2017, 35, 701-707	18
222	Fresh versus Frozen Embryo Transfer in PCOS: Arguments for and Against. 2017, 35, 359-363	2
221	Management of adnexal masses in pregnancy. 2017, 19, 317-325	8
220	Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted. 2017, 108, 650-658.e2	6
219	Sonographic Tips for Evaluation of Adnexal Masses in Pregnancy. 2017, 60, 575-585	3
218	A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. <i>Human Reproduction</i> , 2017, 32, 1915-1924	5.7 33
217	[Which ovarian stimulation to which women: The polycystic ovary syndrome (PCOS)]. 2017, 45, 623-631	3
216	Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion. 2017, 154, 355-362	20
215	Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles. 2017, 16, 52-57	3
214	The Lady Vanishes: Eggs for Reproduction and Research. 46-64	
213	Bibliography. 169-196	

212	Luteal Angiogenesis. 2017 , 1-21		1
211	Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial. 2017 , 216, 42.e1-42.e10		26
210	Clinical Management of Pregnancies following ART. 2017 ,		
209	Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. <i>Human Reproduction</i> , 2017 , 32, 2485-2495	5-7	48
208	No-268-The Diagnosis and Management of Ovarian Hyperstimulation Syndrome. 2017 , 39, e479-e486		5
207	N° 268-Diagnostic et prise en charge du syndrome d'hyperstimulation ovarienne. 2017 , 39, e487-e495		
206	Effects of acupuncture on the levels of serum estradiol and pituitary estrogen receptor beta in a rat model of induced super ovulation. 2018 , 197, 109-113		4
205	The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. <i>Human Reproduction</i> , 2018 , 33, 292-302	5-7	22
204	Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. 2018 , 224, 117-124		9
203	Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines. 2018 , 21, 98-105		11
202	Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. <i>Gynecological Endocrinology</i> , 2018 , 34, 92-99	2-4	4
201	Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: a randomised controlled trial. 2018 , 38, 241-246		4
200	A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. 2018 , 35, 297-307		3
199	Neuroendocrinology of Female Reproduction. 2018 , 29-52		1
198	Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. 2018 , 118, 1962-1968		27
197	Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: A randomized clinical trial. 2018 , 23, 357-362		2
196	Genome-wide screening differential long non-coding RNAs expression profiles discloses its roles involved in OHSS development. 2018 , 35, 1473-1482		3
195	Ovulation Induction With Gonadotropins. 2019 , 570-580		

194	Medical Approaches to Ovarian Stimulation for Infertility. 2019 , 743-778.e7		2
193	A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. 2019 , 39, 281-293		49
192	Sphingosine-1-phosphate (S1P) in ovarian physiology and disease. 2019 , 80, 263-272		8
191	Is oocyte maturity influenced by ovulation trigger type in oocyte donation cycles?. 2019 , 1-7		2
190	Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. 2019 , 19, 145-148		6
189	Do female age and body weight modify the effect of individualized FSH dosing in IVF/ICSI treatment? A secondary analysis of the OPTIMIST trial. 2019 , 98, 1332-1340		2
188	Upregulation of AREG, EGFR, and HER2 contributes to increased VEGF expression in granulosa cells of patients with OHSS 2019 , 101, 426-432		6
187	A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. 2019 , 14, 315-319		11
186	The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count. <i>Human Reproduction</i> , 2019 , 34, 1055-1064	5:7	25
185	The Ethics of the Societal Entrenchment-approach and the case of live uterus transplantation-IVF. 2019 , 22, 557-571		3
184	Ovarian hyperstimulation syndrome: A review for emergency clinicians. 2019 , 37, 1577-1584		19
183	Oligosymptomatic ovarian hyperstimulation syndrome in a spontaneous uneventful pregnancy. A case report. <i>Gynecological Endocrinology</i> , 2019 , 35, 657-660	2:4	2
182	What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?. 2019 , 39, 687-694		6
181	Ovarian hyperstimulation syndrome. A new look at an old problem. <i>Gynecological Endocrinology</i> , 2019 , 35, 651-656	2:4	7
180	Elective egg freezing without medical indications. 2019 , 98, 647-652		22
179	References. 2019 , 179-201		
178	Prediction of efficacy of gonadotropin releasing hormone agonist trigger for final oocyte maturation through post-trigger 12-hour luteinizing hormone, follicle stimulating hormone and progesterone levels in COS: a prospective study. 2019 , 8, 4871		
177	The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation. 2019 , 29, 114-120		8

176	Ovarian Hyperstimulation Syndrome as a Growing Diagnostic Problem in Emergency Department Settings: A Case Report. 2019 , 56, 217-221		6
175	Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development. 2019 , 42, 453-461		2
174	Ovarian Hyperstimulation Syndrome. 2019 , 345-362		
173	The Role of GnRH Agonist Triggering in GnRH Antagonist-Based Ovarian Stimulation Protocols. 2019 , 363-377		
172	Ovarian hyperstimulation syndrome: a clinical retrospective study on 565 inpatients. <i>Gynecological Endocrinology</i> , 2020 , 36, 313-317	2.4	3
171	Antenatal management of singleton pregnancies conceived using assisted reproductive technology. 2020 , 22, 34-44		2
170	The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic. 2020 , 244, 71-75		7
169	The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review. 2020 , 37, 4831-4847		5
168	FRIENDLY PROTOCOL FOR OOCYTE DONORS: FERTILITY OPTIMIZATION IN TIMES OF SOCIAL ISOLATION DUE TO COVID-19?. 2020 , 114, e460-e461		1
167	Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes. 2020 , 114, 567-578		6
166	Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. 2020 , 17, 181		3
165	Constructions of surrogates, egg donors, and mothers: Swedish gay fathers' narratives. 2020 , 30, 508-528		2
164	Trends in ovarian hyperstimulation syndrome hospitalization rates in the USA: an ongoing concern. 2020 , 41, 357-360		2
163	Maternal complications of fetal triploidy: a case report. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	2
162	Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 1341-1350	12.8	6
161	Prediction of severe ovarian hyperstimulation syndrome in women undergoing fertilization using estradiol levels, collected ova, and number of follicles. 2020 , 48, 300060520945551		0
160	TO CANCEL OR NOT TO CANCEL? USING AN ARTIFICIAL NEURAL NETWORK (ANN) TO PREDICT UTILITY OF OOCYTE RETRIEVAL VS. CYCLE CANCELLATION IN EXTREMELY POOR RESPONDERS. 2020 , 114, e459-e460		
159	Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer. 2020 , 125, 131-137		6

158	TGF- β induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 450-460	12.8	12
157	Insulin Resistance and Free Androgen as Predictors for Ovarian Hyperstimulation Syndrome in Non-PCOS Women. 2020 , 52, 104-108		6
156	Pregnancy Outcome Difference between Fresh and Frozen Embryos in Women without Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis. 2021 , 28, 1267-1276		1
155	Neonatal outcomes in women with polycystic ovary syndrome after frozen-thawed embryo transfer. 2021 , 115, 447-454		1
154	Alignment between expectations and experiences of egg donors: what does it mean to be informed?. 2021 , 12, 1-13		3
153	Ovarian Hyperstimulation Syndrome (OHSS). 2021 , 209-221		
152	High ovarian GDF-8 levels contribute to elevated estradiol production in ovarian hyperstimulation syndrome by stimulating aromatase expression. 2021 , 17, 2338-2347		0
151	Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. 2021 , 9, 387		0
150	Safety of Ovaleap β (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 632674	5.7	0
149	Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). 2021 , 4, CD005289		1
148	Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome. <i>Reproductive Biology and Endocrinology</i> , 2021 , 19, 52	5	
147	In vitro fertilization outcomes in women with polycystic ovary syndrome: A meta-analysis. 2021 , 259, 146-152		1
146	In Vitro Maturation of Germinal Vesicle Oocytes. 2021 , 355-363		
145	Superovulation with gonadotropin-releasing hormone agonist or chorionic gonadotropin for ovulation trigger differentially affects leukocyte populations in the peri-implantation mouse uterus.. 2021 , 2, 198-206		
144	Low dose hCG supplementation in a Gn-RH-agonist trigger protocol is associated with worse pregnancy outcomes: a retrospective cohort study. 2021 , 7, 12		0
143	Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017). <i>Reproductive Biology and Endocrinology</i> , 2021 , 19, 68	5	6
142	Assistierte Fertilisation. 2021 , 23, 40-50		
141	Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles. 2021 , 28, 3390-3396		

140	Outcomes comparison of IVF/ICSI among different trigger methods for final oocyte maturation: A systematic review and meta-analysis. 2021 , 35, e21696		2
139	Perspectives on the development and future of oocyte IVM in clinical practice. 2021 , 38, 1265-1280		13
138	The Association between Ovarian Hyperstimulation Syndrome and Pregnancy Complications following Fertility Treatments. 2021 ,		
137	Overview of hospitalizations in women undergoing oocyte retrieval for ART in the French national health data system. <i>Human Reproduction</i> , 2021 , 36, 2769-2781	5.7	0
136	sRAGE downregulates the VEGF expression in OHSS ovarian granulosa cells. <i>Gynecological Endocrinology</i> , 2021 , 37, 836-840	2.4	0
135	The influence of obesity on incidence of complications in patients hospitalized with ovarian hyperstimulation syndrome. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	0
134	Neonatales Outcome nach Kryoembryotransfer bei PCOS-Patientinnen. 2021 , 19, 315		
133	Variants Ala307Ala and Ser680Ser of 307 and 680 FSHr polymorphisms negatively influence on assisted reproductive techniques outcome and determine high probability of non-pregnancy in Caucasian patients. 2021 , 38, 2769-2779		1
132	Coagulation and Fibrinolysis Biomarkers as Potential Indicators for the Diagnosis and Classification of Ovarian Hyperstimulation Syndrome. 2021 , 8, 720342		1
131	Cost-effectiveness modelling of three different hysterosalpingography diagnostic strategies in addition to standard fertility management for couples with unexplained infertility in the United Kingdom. 2021 , 1-10		0
130	Blastocyst Transfer: A risk Factor for Gestational Diabetes Mellitus in Women undergoing in vitro Fertilization. 2021 ,		1
129	GnRHa (alone or combined with hCG) versus hCG alone for ovulation triggering during controlled ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis. 2021 ,		1
128	Infertility, Infertility Treatment, and Cardiovascular Disease: An Overview. 2021 ,		0
127	Triphenyl phosphate delayed pubertal timing and induced decline of ovarian reserve in mice as an estrogen receptor antagonist. 2021 , 290, 118096		4
126	Clinical cases in oncofertility. 2010 , 156, 55-67		4
125	Risk and Complications Associated with Egg Donation. 2013 , 205-219		2
124	Physiology and pathophysiology of the epithelial barrier of the female reproductive tract: role of ion channels. 2012 , 763, 193-217		21
123	Ultrasound and PCOS. 2014 , 75-91		1

122	Assistierte Reproduktion. 2009 , 477-513		0
121	Procuring Tissue: Regenerative Medicine, Oocyte Mobilisation, and Feminist Politics. 2013 , 118-149		3
120	Superovulation with human chorionic gonadotropin (hCG) trigger and gonadotropin releasing hormone agonist (GnRHa) trigger differentially alter essential angiogenic factors in the endometrium in a mouse ART model□ 2020 , 102, 1122-1133		2
119	Sudden Death Due to Severe Ovarian Hyperstimulation Syndrome: An Autopsy-Centric Case Report. 2021 , 42, 88-91		1
118	Ovarian hyperstimulation syndrome in a frozen-thawed embryo transfer pregnancy: a rare case report. 2020 , 20, 313		0
117	Basics of Ovarian Stimulation. 2017 , 55-72		1
116	Delivery after transfer of frozen-thawed embryos from in vitro-matured oocytes in a woman at risk for ovarian hyperstimulation syndrome. 2007 , 53, 449-53		2
115	Radiological illustration of spontaneous ovarian hyperstimulation syndrome. 2015 , 80, 217-27		15
114	Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. 2016 , 11, e0149615		47
113	Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?. 2016 , 8, 396-401		3
112	Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility of ovarian hyperstimulation syndrome. <i>International Journal of Reproductive BioMedicine</i> , 2017 , 15, 87-92	1.3	5
111	Comparison the Effect of Oxytocin and Human Chorionic Gonadotropin on Ovulation. 2007 , 7, 1126-1134		1
110	Ovarian hyperstimulation syndrome in a spontaneous pregnancy: A potential for missed-diagnosis. <i>Nigerian Medical Journal</i> , 2016 , 57, 74-6	0.6	4
109	Hematocrit as a simple method to predict and manage ovarian hyperstimulation syndrome in assisted reproduction. 2015 , 8, 93-7		2
108	Novel FSH receptor mutation in a case of spontaneous ovarian hyperstimulation syndrome with successful pregnancy outcome. 2015 , 8, 230-3		14
107	Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. 2016 , 9, 164-172		18
106	Does the serum E2 level change following coasting treatment strategy to prevent ovarian hyperstimulation syndrome impact cycle outcomes during controlled ovarian hyperstimulation and in vitro fertilization procedure?. 2014 , 11, 159-164		2
105	Three-dimensional Ultrasound in the Fertility Clinic. 2008 , 2, 65-74		2

104	Clinical application of serum anti-Müllerian hormone in women. 2019 , 46, 50-59	24
103	Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS). 2021 , 33, 799-809	0
102	Development and Validation of Prediction Model for High Ovarian Response in Fertilization-Embryo Transfer: A Longitudinal Study. 2021 , 2021, 7822119	1
101	Metastatic choriocarcinoma with hemorrhagic complications and spontaneous ovarian hyperstimulation syndrome: A case report. 2021 , 16, 3868-3874	0
100	Infertility. 2006 , 125-144	
99	Ascites due to ovarian hyperstimulation syndrome: A case report and review of literature. 2007 , 11, 155-160	
98	O. 2007 , 583-611	
97	Pleural Effusion. 2008 , 1336-1371	0
96	Die Technisierung der Zeugung. 2010 , 99-124	
95	Spontaneous bacterial peritonitis complicating ovarian hyperstimulation syndrome-related ascites. 2011 , 66, 2173-5	1
94	Nonmalignant Gynecology. 2011 , 1027-1036.e2	
93	Ovulation induction. 2011 , 231-250	
92	The Patient Over-Responding to Controlled Ovarian Stimulation during IVF. 208-212	
91	The use of cabergoline for treatment of syndrome of ovarian hyperstimulation. 2012 , 9, 48-50	
90	Patient-Tailored Approaches to Ovarian Stimulation in ART. 2013 , 137-153	
89	Pre-hCG variables associated with occurrence of ascites in IVF/ICSI patients at moderate risk of developing OHSS: A pilot investigation. 2013 , 03, 13-20	
88	La ética y la bioética de la programación de la humanidad. 2014 , 11, 41-50	1
87	Speculative Economies, Contingent Bodies. 2014 , 159-194	

86 Notes. **2014**, 229-241

85 Conclusion. **2014**, 221-228

84 Fertility Outsourcing. **2014**, 37-61

83 The Labor of Distributed Experiment. **2014**, 195-219

82 Reproductive Arbitrage. **2014**, 62-88

81 The American Experiment. **2014**, 123-158

80 The Historical Lineages of Clinical Labor. **2014**, 18-32

79 Regenerative Labor. **2014**, 89-115

78 References. **2014**, 243-271

77 Ovarian Hyper Stimulation Syndrome in Two Spontaneous Pregnancies. **2014**, 2,

76 A RARE CASE OF OVARIAN HYPERSTIMULATION AFTER CLOMIPHENE CITRATE RESULTING IN TORSION AND RUPTURE. **2014**, 3, 2373-2377

75 Ovarian Hyperstimulation Syndrome. **2015**, 35-57

74 Neonatal outcome after IVF. **2016**, 22, 65

1

73 Controlled Ovarian Stimulation Protocols in Cancer Patients. **2016**, 21-37

72 Successful treatment of severe ovarian hyperstimulation degree (case report). **2016**, 22, 63

71 Mild Stimulation Cycles versus Controlled Stimulation Cycles: A Japanese Perspective. **2016**, 95-101

70 Ovarian hyperstimulation syndrome with Schistosomiasis: A case report. **2016**, 1, 6

69 Complications of ART and Associated Early Pregnancy Problems. **2017**, 81-100

68	Strategies for Risk Reduction and Improving Success in Women with Medical Comorbidities. 2017 , 221-228		
67	Is Coasting Valuable in All Patients with Any Cause of Infertility?. 2016 , 31, 404-408		2
66	Standard Ovarian Stimulation Protocols and Their Outcomes. 2017 , 129-146		
65	Risk Factors and Preventive Measures of Ovarian Hyperstimulation Syndrome. 2017 , 175-184		
64	Development of IVM Treatment: Combination of Natural Cycle IVF with IVM. 2017 , 359-366		
63	Reproductive Outcomes of Ovarian Hyperstimulation Syndrome (OHSS) in PCO Compare to non-PCO Patients. 2017 , 2, 153-157		0
62	High-Risk Pregnancy: Management Options. 2018 ,		1
61	The effect of early coasting on blastocyst development and outcome following blastocyst transfer in IVF/ICSI programme. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2018 , 22, 301-306	1.7	1
60	Intensive treatment of ovarian hyperstimulation syndrome. Clinical guidelines (treatment protocol). 2018 , 8-25		1
59	Severe early ovarian hyperstimulation syndrome after spontaneous pregnancy and despite GnRH-agonist trigger during controlled ovarian stimulation in an oocyte donor cycle: a case report. 2018 , 7,		
58	Estimulaci3n ov3rica para fecundaci3n in vitro-inyecci3n intracitoplasm3tica de espermatozoides en los ciclos con presunci3n de alta respuesta (2017). 2019 ,		
57	Misoprostol (Cytotec) for Prevention of Ovarian Hyperstimulation Syndrome. A Preliminary Investigation.. 2017 , 1, 19-20		
56	Risk of spontaneous preterm labor in pregnancies achieved by in vitro fertilization and complicated with severe form of ovarian hyperstimulation syndrome: A case control study. 2019 , 35, 923-928		1
55	Letrozole in Fertility Therapy. 2020 , 53-68		0
54	Does the Freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in IVF cycles?.		
53	Effect of exogenous human chorionic gonadotropin on ovulation in mice. <i>Vavilovskii Zhurnal Genetiki i Seleksii</i> , 2020 , 23, 1006-1010	0.9	0
52	CLINICAL CHARACTERISTICS OF PATIENTS WITH INFERTILITY ON THE BACKGROUND OF POLYCYSTIC OVARY SYNDROME USING STANDARD PROTECTION PROTOCOL. <i>Bulletin of Problems Biology and Medicine</i> , 2020 , 4, 238	0.1	
51	Indications for Abdominal Surgery in Spontaneous Ovarian Hyperstimulation: A Literature Review. <i>Journal of Gynecologic Surgery</i> , 2020 , 36, 301-305	0.4	

50	Spontaneous Ovarian Hyperstimulation Syndrome: A Report of Two Cases from Different Pathogenesis. <i>Nigerian Medical Journal</i> , 2020 , 61, 269-272	0.6	1
49	GnRH Agonist Protocols. 2020 , 79-88		
48	HCG trigger versus GnRH agonist trigger in PCOS patients undergoing IVF cycles: frozen embryo transfer outcomes. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2021 , 25, 48-58	1.7	0
47	Venous thrombosis risk factors in pregnant women. <i>Journal of Perinatal Medicine</i> , 2020 ,	2.7	1
46	Thrombophilia and ovarian hyperstimulation syndrome: a case report. <i>Hawaii Medical Journal</i> , 2011 , 70, 97-8		1
45	The use of in vitro fertilization in the management of male infertility: what the urologist needs to know. <i>Reviews in Urology</i> , 2013 , 15, 154-60	1	5
44	Using fertile couples as embryo donors: An ethical dilemma. <i>Iranian Journal of Reproductive Medicine</i> , 2014 , 12, 169-74		
43	Could pretreatment with oral contraceptives before pituitary down regulation reduce the incidence of ovarian hyperstimulation syndrome in the IVF/ICSI procedure?. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 2711-8		3
42	Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome. <i>Medical Journal of the Islamic Republic of Iran</i> , 2016 , 30, 371	1.1	1
41	Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome. <i>International Journal of Reproductive BioMedicine</i> , 2017 , 15, 87-92	1.3	4
40	Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. <i>Iranian Journal of Medical Sciences</i> , 2018 , 43, 248-260	1.2	25
39	Non-syndromic monogenic female infertility. <i>Acta Biomedica</i> , 2019 , 90, 68-74	3.2	10
38	Rescue Maturation in Polycystic Ovarian Syndrome Patients Undergoing Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study. <i>International Journal of Fertility & Sterility</i> , 2020 , 14, 137-142	1.9	
37	Anti-Müllerian Hormone Predictive Levels to Determine The Likelihood of Ovarian Hyper-Response in Infertile Women with Polycystic Ovarian Morphology. <i>International Journal of Fertility & Sterility</i> , 2021 , 15, 115-122	1.9	
36	Effect of dual trigger on reproductive outcome in low responders: a systematic PRISMA review and meta-analysis. <i>Gynecological Endocrinology</i> , 2021 , 1-9	2.4	
35	Ovarian hyperstimulation syndrome: cardiac arrest with an unexpected outcome. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1
34	Does the freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in IVF cycles?. <i>Archives of Gynecology and Obstetrics</i> , 2021 ,	2.5	0
33	Venous thrombosis risk factors in pregnant women.. <i>Journal of Perinatal Medicine</i> , 2022 ,	2.7	1

32	Tie1 contributes to the development of ovarian hyperstimulation syndrome under the regulation of EGR1 in granulosa cells.. <i>Experimental and Molecular Medicine</i> , 2022 ,	12.8	
31	Assistierte Reproduktion. <i>Springer Reference Medizin</i> , 2021 , 1-30	0	
30	Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model.. <i>Drug Design, Development and Therapy</i> , 2022 , 16, 397-411	4.4	
29	Recombinant Human Follicle-Stimulating Hormone Alfa Dose Adjustment in US Clinical Practice: An Observational, Retrospective Analysis of a Real-World Electronic Medical Records Database.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 742089	5.7	0
28	Ovarian Hyperstimulation Syndrome Risk Factors in Assisted Reproductive Technologies (Review). 2020 , 475-489		
27	GnRH Agonists for Ovarian Hyperstimulation. 2022 , 55-64		
26	OUP accepted manuscript. <i>Human Reproduction</i> ,	5.7	0
25	Assisted Reproductive Technology: Clinical Aspects. 2022 , 367-391		
24	Predictive Factors for Recovery Time in Conceived Women Suffering From Moderate to Severe Ovarian Hyperstimulation Syndrome. <i>Frontiers in Endocrinology</i> , 13,	5.7	
23	Risk of Higher Blood Pressure in 3 to 6 Years Old Singleton Born From OHSS Patients Undergone With Fresh IVF/ICSI. <i>Frontiers in Endocrinology</i> , 13,	5.7	
22	Myostatin: a multifunctional role in human female reproduction and fertility a short review. <i>Reproductive Biology and Endocrinology</i> , 2022 , 20,	5	1
21	The Use of Assisted Reproductive Technology by European Childhood Cancer Survivors. 2022 , 29, 5748-5762		1
20	Relationship Between Number of Oocytes Retrieved and Embryo Euploidy Rate in Controlled Ovarian Stimulation Cycles.		
19	Assisted reproduction in patients with cardiac disease: A retrospective review. 2022 , 276, 199-203		0
18	Talking about assisted reproductive techniques and thromboembolic risk: everything we always wanted to know. 2022 , 1,		0
17	GnRH agonist-triggering ovulation in women with advanced age. 2022 , 12,		0
16	Severe ovarian hyperstimulation syndrome induced by clomiphene: a case report. 1-6		0
15	To curette or not to curette; efficiency of oocyte retrieval technique. 2022 , 306, 1771-1776		0

- 14 Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment. 13, 0
- 13 A multicenter, randomized, assessor-blind phase 3 trial comparing the efficacy and safety of QL1012 (recombinant human follicle-stimulating hormone) with Gonal-f[®] in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. **2022**, 0
- 12 Rapamycin improves developmental competence of human oocytes by alleviating DNA damage during IVM. 1
- 11 As Sure As Eggs? Responses to an Ethical Question Posed by Abramov, Elchalal, and Schenker. **2007**, 18, 35-48 0
- 10 Perinatal outcomes of singleton live births after late moderate-to-severe ovarian hyperstimulation syndrome: A propensity score-matched study. 13, 0
- 9 Letrozole increases preantral follicle growth and decreases estradiol production without impairing follicle survival. **2022**, 15, 0
- 8 Pregnancy outcomes in patients receiving assisted reproductive therapy with systemic lupus erythematosus: a multi-center retrospective study. **2023**, 25, 0
- 7 Ovarian hyperstimulation syndrome. **2023**, 223-239 0
- 6 Challenges of OHSS in modern reproductive medicine practice. **2023**, 10, 6 0
- 5 m.4216 T > C polymorphism in JT cluster determines a lower pregnancy rate in response to controlled ovarian stimulation treatment. **2023**, 40, 671-682 0
- 4 Comparison of pregnancy outcomes of letrozole-induced frozen-thawed embryo transfer cycles in PCOS women with two different abnormal ovulation patterns: A retrospective cohort study. **2023**, 102, e33049 0
- 3 Cumulative live birth rate after oocyte in vitro maturation with a pre-maturation step in women with polycystic ovary syndrome or high antral follicle count. 0
- 2 Association between HOMA-IR and ovarian sensitivity index in women with PCOS undergoing ART: A retrospective cohort study. 14, 0
- 1 Hyperstimulated: A case of ovarian hyperstimulation syndrome seen on bedside ultrasound in the emergency department. **2023**, 31, 101679 0